Questcor Pharmaceuticals, Inc. (Headquarters) Resubmits Supplemental New Drug Application to FDA for H.P. Acthar(R) Gel for Treatment of Infantile Spasms

UNION CITY, Calif., Oct. 15, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced that it has resubmitted its filing to the U.S. Food & Drug Administration (FDA) for its supplemental New Drug Application (sNDA) seeking approval to market H.P. Acthar(R) Gel (repository corticotrophin injection) for the treatment of infantile spasms. The resubmission follows the FDA’s request in May 2009 for the filing to include additional statistical analysis relating to data from one secondary study within the Company’s filing.